BR0312484A - compostos e métodos para tratamento terapêutico - Google Patents
compostos e métodos para tratamento terapêuticoInfo
- Publication number
- BR0312484A BR0312484A BRPI0312484-3A BR0312484A BR0312484A BR 0312484 A BR0312484 A BR 0312484A BR 0312484 A BR0312484 A BR 0312484A BR 0312484 A BR0312484 A BR 0312484A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- agent
- methods
- present
- therapeutic treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18902502A | 2002-07-01 | 2002-07-01 | |
PCT/US2003/020604 WO2004002528A1 (en) | 2002-07-01 | 2003-06-30 | Compositions and methods for therapeutic treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312484A true BR0312484A (pt) | 2008-01-08 |
Family
ID=29999592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0312484-3A BR0312484A (pt) | 2002-07-01 | 2003-06-30 | compostos e métodos para tratamento terapêutico |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1551452A4 (ru) |
JP (1) | JP2005534679A (ru) |
KR (1) | KR20050059001A (ru) |
CN (1) | CN1678348A (ru) |
AU (1) | AU2003279657A1 (ru) |
BR (1) | BR0312484A (ru) |
CA (1) | CA2491427A1 (ru) |
IL (1) | IL166062A0 (ru) |
MX (1) | MXPA05000271A (ru) |
PL (1) | PL374431A1 (ru) |
RU (1) | RU2005101622A (ru) |
WO (1) | WO2004002528A1 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003256299A1 (en) | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
WO2005094863A1 (en) * | 2004-03-30 | 2005-10-13 | Den Kgl.Veterinær-Og Landbohøjskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and decting protease inhibitors |
US10092662B2 (en) * | 2004-03-31 | 2018-10-09 | University Of Utah Research Foundation | Macromolecular delivery systems for non-invasive imaging, evaluation and treatment of arthritis and other inflammatory diseases |
WO2007038637A2 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
EP2373343B1 (en) | 2008-12-19 | 2015-02-11 | Philogen S.p.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
EP4079324A1 (en) * | 2014-07-08 | 2022-10-26 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
US10472422B2 (en) * | 2016-01-08 | 2019-11-12 | Abgenomics International Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05244987A (ja) * | 1992-02-28 | 1993-09-24 | Unitika Ltd | 抗硫酸化チロシン抗体,その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ |
US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
BR9912053A (pt) * | 1998-07-13 | 2001-04-03 | Univ Texas | Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios |
EP1131084A4 (en) * | 1998-10-30 | 2001-12-19 | Genetics Inst | INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL) |
WO2001085205A1 (en) * | 2000-05-11 | 2001-11-15 | National Tsing Hua University | Compositions and methods for induction of active autoimmunity |
PL360153A1 (en) * | 2000-05-15 | 2004-09-06 | Pharmacia & Upjohn S.P.A. | Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents |
CN100347194C (zh) * | 2000-12-29 | 2007-11-07 | 萨文特医药公司 | 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用 |
MXPA03005944A (es) * | 2000-12-29 | 2005-04-29 | Bio Technology General Corp | Anticuerpos humanos especificos para terapia selectiva de cancer. |
-
2003
- 2003-06-30 KR KR1020047021602A patent/KR20050059001A/ko not_active Application Discontinuation
- 2003-06-30 RU RU2005101622/15A patent/RU2005101622A/ru not_active Application Discontinuation
- 2003-06-30 WO PCT/US2003/020604 patent/WO2004002528A1/en active Application Filing
- 2003-06-30 MX MXPA05000271A patent/MXPA05000271A/es unknown
- 2003-06-30 AU AU2003279657A patent/AU2003279657A1/en not_active Abandoned
- 2003-06-30 CN CNA03820441XA patent/CN1678348A/zh active Pending
- 2003-06-30 BR BRPI0312484-3A patent/BR0312484A/pt not_active IP Right Cessation
- 2003-06-30 CA CA002491427A patent/CA2491427A1/en not_active Abandoned
- 2003-06-30 PL PL03374431A patent/PL374431A1/xx not_active Application Discontinuation
- 2003-06-30 EP EP03742338A patent/EP1551452A4/en not_active Withdrawn
- 2003-06-30 JP JP2004518133A patent/JP2005534679A/ja active Pending
-
2004
- 2004-12-30 IL IL16606204A patent/IL166062A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005534679A (ja) | 2005-11-17 |
WO2004002528A1 (en) | 2004-01-08 |
EP1551452A1 (en) | 2005-07-13 |
KR20050059001A (ko) | 2005-06-17 |
CN1678348A (zh) | 2005-10-05 |
CA2491427A1 (en) | 2004-01-08 |
AU2003279657A1 (en) | 2004-01-19 |
EP1551452A4 (en) | 2006-08-30 |
IL166062A0 (en) | 2006-01-15 |
MXPA05000271A (es) | 2005-03-31 |
RU2005101622A (ru) | 2006-01-27 |
PL374431A1 (en) | 2005-10-17 |
WO2004002528A9 (en) | 2004-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0312398B8 (pt) | derivado de 1,3-difenilprop-2-en-1-ona substituído, processo de preparação de compostos, composição farmacêutica e utilização de pelo menos um derivado de 1,3-difenilprop-2-en-1-ona substituído | |
UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
AR031534A1 (es) | Composiciones para el tratamiento del cabello | |
BR0310088A (pt) | Pré-direcionamento de droga por meio de anticorpos biespecìficos e constructos haptênicos compreendendo um veìculo peptìdico e o(s) agente(s) ativo(s) | |
AR088110A2 (es) | Uso de un inmunoconjugado que comprende un anticuerpo anti-erbb2 para la manufactura de un medicamento | |
BRPI0507189A (pt) | uso combinado de um agonista de glp-1 e compostos de gastrina | |
BRPI0414876A (pt) | compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos | |
BRPI0109131B8 (pt) | dna, vetor de expressão compreendendo o mesmo, fator viii modificado de porcino, seu processo de produção e composição terapêutica compreendendo o mesmo | |
BRPI0414435A (pt) | métodos e reagentes para o tratamento de distúrbios imunoinflamatórios | |
BR0110993A (pt) | Composto, composição farmacêutica compreendendo o mesmo e método | |
AR038605A1 (es) | Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento | |
BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
Aggarwal et al. | In vitro evaluation of effect of various endodontic solutions on selected physical properties of white mineral trioxide aggregate | |
WO2003004000A3 (en) | Topical composition for treating pain | |
BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
BRPI0411295A (pt) | compostos e seu uso na terapia | |
BRPI0513278A (pt) | uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton | |
NO20023473D0 (no) | Sammensetninger for levering av en kortisol antagonist | |
BR0312484A (pt) | compostos e métodos para tratamento terapêutico | |
ATE359068T1 (de) | Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen | |
BR0113625A (pt) | Exemestano como agente de quimioprevenção | |
BRPI0409742A (pt) | uso de um agente anti-angiogênico, em combinação com um inibidor da famìlia src de tirosina quinases não-receptoras, produto de combinação, e, composição farmacêutica | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A. E 7A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010. |